NeuroVigil, Inc.
PrivateLast Round
Series B
Apr 5, 2024
Est. Valuation
$6B
Total Funding Raised
$85.28M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NeuroVigil, Inc. operates in Healthcare & Life Sciences and is based in Mountain View, California. Its latest recorded funding round was a Series B round in April 2024.
NeuroVigil, Inc. is a neurotechnology company that develops proprietary non-invasive brain monitors and advanced machine learning algorithms to detect a constellation of biomarkers of pathologies in asymptomatic individuals.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Medical AI, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroVigil, Inc. Comparables
Compare NeuroVigil, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Beacon Biosignals | 83% | |
| Firefly Neuroscience, Inc. | 80% | |
| Cumulus Neuroscience | 79% |
For institutional investors. Book with your work email.
NeuroVigil, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 5, 2024 | ||||
| Series A | May 4, 2015 | ||||
| Seed | May 2, 2011 | ||||
| Grant | Jul 2, 2008 | ||||
| Seed | May 30, 2008 |
For institutional investors. Book with your work email.
NeuroVigil, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DFJ Frontier | Seed |
| Zone Ventures | Series A, Seed |
| University of Waterloo | Series B |
| Draper Fisher Jurvetson Management | Series A, Seed |
| DFJ Growth | Series A |
| Draper Associates | Series A, Seed |
| Wilson Sonsini Goodrich & Rosati | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 492% MoM, reaching 2.1K.
- Oct 10, 2025
Named a Top 10 Most Innovative Company in Health Care by Fast Company.
For institutional investors. Book with your work email.
NeuroVigil, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroVigil, Inc.'s valuation, stock price, and market status.
Is NeuroVigil, Inc. a public or private company?
NeuroVigil, Inc. is a private company.
What is the current stock price of NeuroVigil, Inc.?
NeuroVigil, Inc. is a private company, so its shares have no public market price. Caplight tracks NeuroVigil, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroVigil, Inc. worth (valuation)?
NeuroVigil, Inc.'s valuation is estimated at $6.0B based on funding round data.
Can I buy NeuroVigil, Inc. stock?
NeuroVigil, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroVigil, Inc.'s last funding round?
NeuroVigil, Inc.'s most recent funding round was Series B on April 5, 2024.
Who are the main investors in NeuroVigil, Inc.?
Key investors in NeuroVigil, Inc. include DFJ Frontier, Zone Ventures, University of Waterloo, Draper Fisher Jurvetson Management, DFJ Growth.
Will NeuroVigil, Inc. IPO soon?
No public IPO plans have been announced for NeuroVigil, Inc..
How can I track NeuroVigil, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in NeuroVigil, Inc.'s shares on secondary markets.